BioSeek, a subsidiary of Asterand, has signed a two-year collaboration agreement with Eisai to advance the discovery of oncology and inflammation agents.

BioSeek will apply its proprietary BioMAP platform to advance Eisai’s drug discovery in oncology and inflammation segments at Eisai’s sites in Japan and the US.

BioMAP is a human-based disease model designed to replicate the intricate cell and pathway interactions observed in human pharmacology and toxicology.

The platform also provides early insights into pharmacological and toxicological properties of compounds, including on and off-target effects and dose responses.

The financial terms are not disclosed but would include research funding, milestone payments and license fees.